Floatz logo

CHLORHEXIDINE

Methicillin-resistant Staphylococcus Aureus

University of North Carolina, Chapel HillSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Methicillin-resistant Staphylococcus Aureus cohort.

Asset / SponsorPhaseRating
SULFAMETHOXAZOLE
University of North Carolina, Chapel Hill
Phase 4BBB
Trimethoprim
University of North Carolina, Chapel Hill
Phase 4BBB
RIFALDAZINE
Johns Hopkins University
Phase 4BB
Vancomycin
Savara Inc.
Phase 3BB
CEFADROXIL ANHYDROUS
Mayo Clinic
Phase 4BB

View all 9 →

Same molecule, other indications

CHLORHEXIDINE is also rated in:

Wound InfectionDormant
BBB
Indicative ·
73 / 100
View asset →
Wound BreakdownDormant
BB
Indicative ·
69 / 100
View asset →
periodontitisDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →